Lilly slips on outlook
This article was originally published in Scrip
Lilly's share price was trading down by 1% at $69.03 in mid-afternoon trading on 7 January after the company released a financial update that fell below analysts' expectations for 2015 and included a downgrade for its 2014 earnings.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.